Pretax profit more than doubled, revenue grows 10% year-on-year on new client wins in both Pension Actuarial and Pension Investment, interim dividend up 4% from a year prior. Looking ahead, expects annual results to meet management expectations. With it's circa 5% divi and fairly stable price this share is a very easy long term hold for me with buys on dips as and when.
You are not alone. Still a couple of weeks until the year trial is up though. I have convinced myself that, after such a long time it can only be good news when it comes and our patience will be rewarded but you just never know until the RNS.
Well done XPS Pensions Group for, after a competitive tender process, being appointed as pensions advisory partner to BT Group Plc who have one of the UK's largest occupational pension schemes with 280,000 members and assets of over £50 billon. Going from strength to strength.
(set up by the EKF boys) bought 416666 POLX shares at 60p for £250000 in the placing (17th March 21) so they are set to do very nicely out of POLX (amongst their other investments) yet IIG's share price has hardly moved with this latest spike. Have taken a position there as a side bet. (Had to open a new account with HL as IWEB don't trade in IIG for some reason)
RE: Lots of good non-RNS news flow23 Sep 2021 20:32
Rivaldo. Thanks for this and your other posts on this board. Very helpful. One more top up on CAPD for me, maybe tomorrow, and I'm fully loaded. Then hold for the foreseeable. SP growth potential looks very good and they even pay a dividend.
- Record pre-R&D operating profit ahead of market expectations reflecting continued sales growth - Successful ex-vivo VLP Peanut biomarker study showing 24-fold reduction in allergenicity and beneficial efficacy profile paving the way for first-in-human trial in 2022 - Strong cash balance of £40.3m providing sufficient funds with a small amount of debt under current assumptions to support Grass MATA MPL pivotal Phase III field studies and Phase I VLP Peanut PROTECT trial Financial highlights · 8% revenue growth in actual terms and 6% at constant rate* to £84.3m (2020: £78.2m) · 19% increase in pre-R&D operating profit to £16.9m (2020: £14.2m) as a result of sales growth and lower overhead cost growth · Strong cash balance of £40.3m at 30 June 2021 (2020: £37.0m) · Net profit of £2.9m for the year (2020: Net profit of £7.1m including cash settlement of £3.2m)
Operating highlights (including post period) · Successful ex-vivo VLP Peanut biomarker study ahead of Phase I trial (named PROTECT) anticipated in Q1 2022 · Robust growth across all key products and countries in a challenging year · Successful launch of ImmunoBON in Germany and Austria · Grass MATA MPL exploratory field trial to read out in autumn 2021 · Registration of Venomil in Austria Manuel Llobet, CEO of Allergy Therapeutics, stated: "Allergy Therapeutics has performed well in 2021, driving our European commercial business and progressing our clinical programmes amid challenging conditions. Our commercial and pipeline products demonstrate our commitment to allergy and immunology solutions to help people worldwide. "Engaging with our stakeholders is key to our success as a business. They trust us to deliver safe and effective products on time, to stand by our values and to operate our business with high standards of quality and integrity. Our three core values - Vision, Commitment and Menschlichkeit (Humanity), shape the way in which we work and are at the heart of every decision we make. I would like to thank our team and all our partners for their contribution to another successful year." Analyst briefing and webcast today
Manuel Llobet, Chief Executive Officer, Nick Wykeman, Chief Financial Officer, and Alan Bullimore, Head of Business Innovation, will host a virtual presentation for analysts to provide an update on the Group, followed by a Q&A session, at 09.30am BST. The live webcast can be accessed here.